Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Caffeine (200 mg), triptans, NSAID (Nonsteroidal anti-inflammatory drugs), Paracetamol (acetaminophen).
- Who it may be relevant to
- Registry conditions: Migraine, Migraine Disease, Migraine Headache, Migraine Headache, With or Without Aura. Basic parameters: 18 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Assessment of Oral Caffeine Intake in Reducing the Severity of Acute Migraine Attack Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals: A Randomized Controlled Trial
Overview
Caffeine extracted from green tea to abort acute attack of Migraine
Detailed description
Caffeine tablets extracted from green tea can be used as caffeinated drinks to decrease intensity of migraine attacks
Interventions
- Drug Caffeine (200 mg)
caffeine tablets - Drug triptans
Sumatriptan - Drug NSAID (Nonsteroidal anti-inflammatory drugs)
Aspirin 250 mg, 81 mg, 75 mg - Drug Paracetamol (acetaminophen)
Paracetamol 250 mg
Primary outcome measures
- To reduce the severity of migraine attack [Time frame: Three years]
Secondary outcome measures (1)
- To evaluate the effect of oral caffeine in reducing pain associated with acute migraine attacks among patients attending Headache Clinic, Ain Shams University hospital via Visual analogue scale [Time frame: Three year]
Eligibility criteria
Inclusion criteria
Patients suffering from migraine with aura, migraine without aura, episodic, and chronic migraine according to ICHD-3 diagnosis will be legible for the study.
Exclusion criteria
Patients who have history of any cardiac dysrhythmia, hypertension, ischemic heart disease, active peptic ulcer disease, inflammatory bowel disease, obsessive compulsive disorder, pregnancy, breast-feeding, renal failure, hepatic failure, sleep disorder, mental retardation, and history of substance abuse that prevent them from cooperating with us during the study Patients who had headache due to: Cluster headache, trigeminal neuralgia, glossopharyngeal neuralgia, headache secondary to trauma, cranial disorder, vascular disorder, infection, or mass lesion, will also be excluded
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Ainshams university — Cairo
Identifiers
NCT: NCT07022496 · FMASU MD87/2023